Citigroup
INDV icon

Citigroup’s Indivior Pharmaceuticals INDV Stock Holding History

Citigroup’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.4M Buy
643,006
+588,521
+1,080% +$21.3M 0.01% 1015
2026
Q1 		$1.66M Sell
54,485
-37,562
-41% -$1.24M ﹤0.01% 2792
2025
Q4 		$3.3M Buy
92,047
+55,064
+149% +$1.68M ﹤0.01% 2313
2025
Q3 		$892K Sell
36,983
-161,378
-81% -$3.38M ﹤0.01% 3229
2025
Q2 		$2.95M Buy
198,361
+61,901
+45% +$721K ﹤0.01% 2340
2025
Q1 		$1.28M Sell
136,460
-859,865
-86% -$9.04M ﹤0.01% 3071
2024
Q4 		$12.8M Buy
996,325
+751,424
+307% +$7.73M 0.01% 1222
2024
Q3 		$2.42M Buy
244,901
+20,147
+9% +$236K ﹤0.01% 2495
2024
Q2 		$3.52M Sell
224,754
-42,632
-16% -$769K ﹤0.01% 1888
2024
Q1 		$5.72M Sell
267,386
-56,075
-17% -$1.05M ﹤0.01% 1612
2023
Q4 		$4.89M Buy
323,461
+169,693
+110% +$3.01M ﹤0.01% 1615
2023
Q3 		$3.34M Sell
153,768
-59,658
-28% -$1.36M ﹤0.01% 1651
2023
Q2 		$4.95M Buy
+213,426
New +$4.89M ﹤0.01% 1493

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup's INDV Position: Q2 2026 in Review

Citigroup increased its Indivior Pharmaceuticals (INDV) stake by 1,080% in Q2 2026, buying an estimated $21.3M and bringing the position to 643,006 shares worth $26.4M. The position accounts for 0.01% of the portfolio, ranked #1015.

Citigroup first reported a position in INDV in Q2 2023 and has held it in 13 quarters since. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Citigroup held 643,006 shares of Indivior Pharmaceuticals worth $26.4M as of Q2 2026.
  • Citigroup bought 588,521 Indivior Pharmaceuticals shares in Q2 2026, an estimated $21.3M.
  • Indivior Pharmaceuticals made up 0.01% of Citigroup's portfolio in Q2 2026, its #1015 holding.
  • Citigroup first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.